{"id":101783,"date":"2026-05-29T15:40:09","date_gmt":"2026-05-29T10:10:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=101783"},"modified":"2026-05-29T15:40:10","modified_gmt":"2026-05-29T10:10:10","slug":"themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/","title":{"rendered":"Themis Medicare Q4 FY26 Results: Revenue Rs 76.53 Crore, Net Profit Rs 23.92 Crore and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><strong><a href=\"https:\/\/univest.in\/user\/stocks\/themismed\/themis-medicare-ltd-share-price-today?params=themismed&amp;params=themis-medicare-ltd-share-price-today&amp;cacheClear=1780049332138\">Themis Medicare<\/a> Q4 FY26 results<\/strong> were declared on May 28, 2026. The company reported net profit of Rs 23.92 crore for the quarter ended March 31, 2026. Revenue from operations was Rs 76.53 crore. Themis Medicare is a Pharmaceutical Formulations company listed on Indian stock exchanges.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here &#8211; Get Free Investment Predictions<\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Themis_Medicare_Q4_FY26_Financial_Highlights\" title=\"Themis Medicare Q4 FY26 Financial Highlights\">Themis Medicare Q4 FY26 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Themis_Medicare_Q4_FY26_Performance_Analysis\" title=\"Themis Medicare Q4 FY26 Performance Analysis\">Themis Medicare Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Key_Business_Factors_in_Q4_FY26\" title=\"Key Business Factors in Q4 FY26\">Key Business Factors in Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Revenue_and_Volume_Performance\" title=\"Revenue and Volume Performance\">Revenue and Volume Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Profitability_and_Margin_Trajectory\" title=\"Profitability and Margin Trajectory\">Profitability and Margin Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Sector_and_Macro_Backdrop\" title=\"Sector and Macro Backdrop\">Sector and Macro Backdrop<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#FY27_Outlook\" title=\"FY27 Outlook\">FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Themis_Medicare_Stock_Performance\" title=\"Themis Medicare Stock Performance\">Themis Medicare Stock Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Revenue_and_Demand_Risk\" title=\"Revenue and Demand Risk\">Revenue and Demand Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Margin_and_Cost_Volatility\" title=\"Margin and Cost Volatility\">Margin and Cost Volatility<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Frequently_Asked_Questions_on_Themis_Medicare_Q4_FY26_Results\" title=\"Frequently Asked Questions on Themis Medicare Q4 FY26 Results\">Frequently Asked Questions on Themis Medicare Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#What_is_Themis_Medicare_Q4_FY26_net_profit\" title=\"What is Themis Medicare Q4 FY26 net profit?\">What is Themis Medicare Q4 FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#What_is_Themis_Medicare_Q4_FY26_revenue\" title=\"What is Themis Medicare Q4 FY26 revenue?\">What is Themis Medicare Q4 FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#When_were_Themis_Medicare_Q4_FY26_results_declared\" title=\"When were Themis Medicare Q4 FY26 results declared?\">When were Themis Medicare Q4 FY26 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#What_is_the_FY27_outlook_for_Themis_Medicare\" title=\"What is the FY27 outlook for Themis Medicare?\">What is the FY27 outlook for Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#Is_Themis_Medicare_a_good_stock_to_buy_after_Q4_FY26_results\" title=\"Is Themis Medicare a good stock to buy after Q4 FY26 results?\">Is Themis Medicare a good stock to buy after Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/themis-medicare-q4-fy26-net-profit-rs-23-92-cr-results\/#What_sector_does_Themis_Medicare_operate_in\" title=\"What sector does Themis Medicare operate in?\">What sector does Themis Medicare operate in?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Themis_Medicare_Q4_FY26_Financial_Highlights\"><\/span><strong>Themis Medicare Q4 FY26 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Q4 FY25<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<tr>\n<td><strong>Revenue from Operations (Rs Cr)<\/strong><\/td>\n<td>76.53<\/td>\n<td>Prior Year<\/td>\n<td>See BSE\/NSE filing<\/td>\n<\/tr>\n<tr>\n<td><strong>Net Profit (PAT) (Rs Cr)<\/strong><\/td>\n<td>23.92<\/td>\n<td>Prior Year<\/td>\n<td>See BSE\/NSE filing<\/td>\n<\/tr>\n<tr>\n<td><strong>Reporting Basis<\/strong><\/td>\n<td colspan=\"3\">Standalone \/ Consolidated (see BSE\/NSE filing)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Data sourced from company filings and public disclosures. Always verify from BSE\/NSE audited filings before investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Themis_Medicare_Q4_FY26_Performance_Analysis\"><\/span><strong>Themis Medicare Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Themis Medicare Q4 FY26 results<\/strong> reflect performance in the January to March 2026 quarter. Revenue was Rs 76.53 crore as per the audited filing. Net profit of Rs 23.92 crore reflects the company operational performance. Themis Medicare operates in the Pharmaceutical Formulations sector.<\/p>\n<p>India macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth above 6.5%, government capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Formulations sector benefited from these structural tailwinds during the January to March 2026 quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Q4_FY26\"><\/span><strong>Key Business Factors in Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_and_Volume_Performance\"><\/span><strong>Revenue and Volume Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue from operations was Rs 76.53 crore in Q4 FY26 for <strong>Themis Medicare<\/strong>. The Pharmaceutical Formulations sector benefited from India domestic demand recovery and infrastructure push in FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Profitability_and_Margin_Trajectory\"><\/span><strong>Profitability and Margin Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Q4 FY26 net profit of Rs 23.92 crore demonstrates the company performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Sector_and_Macro_Backdrop\"><\/span><strong>Sector and Macro Backdrop<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Formulations sector benefited from these structural tailwinds during the quarter ended March 31, 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook\"><\/span><strong>FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following the <strong>Themis Medicare Q4 FY26 results<\/strong>, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and business strategy. India GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Themis Medicare in FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Themis_Medicare_Stock_Performance\"><\/span><strong>Themis Medicare Stock Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track live price and daily stock recommendations.<\/p>\n<p>Shares of Themis Medicare are listed on NSE and BSE. Following the Q4 FY26 results on May 28, 2026, investors should monitor post-results price action and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_and_Demand_Risk\"><\/span><strong>Revenue and Demand Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any deceleration in India GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Themis Medicare products and services in the Pharmaceutical Formulations sector in FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margin_and_Cost_Volatility\"><\/span><strong>Margin and Cost Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks. Any cost escalation without corresponding pricing power could compress profitability.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Themis Medicare Q4 FY26 results declared on May 28, 2026 showed net profit of Rs 23.92 crore. Investors should monitor management guidance and sector trends before making investment decisions.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE\/NSE audited filings.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Themis_Medicare_Q4_FY26_Results\"><\/span><strong>Frequently Asked Questions on Themis Medicare Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Themis_Medicare_Q4_FY26_net_profit\"><\/span><strong>What is Themis Medicare Q4 FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Themis Medicare Q4 FY26 net profit was Rs 23.92 crore. Results declared May 28, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Themis_Medicare_Q4_FY26_revenue\"><\/span><strong>What is Themis Medicare Q4 FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Themis Medicare Q4 FY26 revenue was Rs 76.53 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Themis_Medicare_Q4_FY26_results_declared\"><\/span><strong>When were Themis Medicare Q4 FY26 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Themis Medicare Q4 FY26 results were declared on May 28, 2026 at the board meeting approving audited financial statements for the quarter and year ended March 31, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Themis_Medicare\"><\/span><strong>What is the FY27 outlook for Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Following Themis Medicare Q4 FY26 results, management guidance on revenue growth, margin improvement, and sector dynamics shapes FY27 expectations. Consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Themis_Medicare_a_good_stock_to_buy_after_Q4_FY26_results\"><\/span><strong>Is Themis Medicare a good stock to buy after Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investment decisions require assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This content is educational only. Consult a SEBI-registered financial advisor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Themis_Medicare_operate_in\"><\/span><strong>What sector does Themis Medicare operate in?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Themis Medicare operates in the Pharmaceutical Formulations sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 28, 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Themis Medicare Q4 FY26 results declared May 28, 2026. Revenue Rs 76.53 Cr. PAT Rs 23.92 Cr. Pharmaceutical Formulations. Key highlights and FY27 outlook.<\/p>\n","protected":false},"author":28,"featured_media":101826,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-101783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1780049414:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_title":["Themis Medicare Q4 FY26: Rev Rs 76.53 Cr, PAT Rs 23.92 Cr"],"rank_math_description":["Themis Medicare Q4 FY26 results declared May 28, 2026. Revenue Rs 76.53 Cr. PAT Rs 23.92 Cr. Pharmaceutical Formulations. Key highlights and FY27 outlook."],"rank_math_focus_keyword":["Themis Medicare Q4"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["101826"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["14341"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/05\/Themis-Medicare-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/101783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=101783"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/101783\/revisions"}],"predecessor-version":[{"id":101828,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/101783\/revisions\/101828"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/101826"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=101783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=101783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=101783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}